Publications by authors named "Dominik Paul Modest"

Claim this Profile
I
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in Wild-Type Metastatic Colorectal Cancer.
Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, Beatrice Borelli, Theresa Keller

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
Alexej Ballhausen, Federica Morano, Arndt Stahler, Sara Lonardi, Andreas Jay Kind, Dominik Paul Modest

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Alessandra Raimondi, Gabriele Tinè, Alexej Ballhausen, Sara Lonardi, David Tougeron, Dominik Paul Modest

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
Lena Weiss, Sebastian Stintzing, Dominik Paul Modest, Arndt Stahler, Ludwig Fischer von Weikersthal

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
Kathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Dominik Paul Modest

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trial.
Thomas Aparicio, Anthony Turpin, Aziz Zaanan, Christelle de la Fouchardière, Karine Le Malicot, Dominik Paul Modest

Dig Liver Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Simone Oldani, Dominik Paul Modest

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Role of Frailty and Its Recognition With Simple FRAIL and Fried Frailty Questionnaires in Advanced Cancer Patients.
Pia Weinländer, Sara Hadzibegovic, Jan Porthun, Lucie Kretzler, Ruben Evertz, Dominik Paul Modest

J Cachexia Sarcopenia Muscle· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with KRAS-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, Taito Esaki, David Páez Lopez-Bravo

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory G12C Colorectal Cancer.
Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, David Paez Lopez-Bravo

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival in the CAIRO5 Clinical Trial.
Alexej Ballhausen, Dominik Paul Modest

JAMA Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, Kathrin Heinrich, Lena Weiss, Dominik Paul Modest

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
Lena Weiss, Sebastian Stintzing, Arndt Stahler, C Benedikt Westphalen, Ludwig Fischer von Weikersthal, Dominik Paul Modest

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
Sebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, Martin Fuchs, Florian Kaiser, Dominik Paul Modest

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solidifying local ablation in the treatment of small-size colorectal liver metastasis.
Laura Stöffler, Dominik Paul Modest, Johann Pratschke, Philipp Konstantin Haber

Lancet Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-based variations in surgical management of colorectal liver metastases: comprehensive analysis.
Pia F Koch, Kristina Ludwig, Karl H Hillebrandt, Hannes Freitag, Moritz Blank, Dominik Paul Modest

BMC Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients.
Phillip Schiele, Stefan Kolling, Stanislav Rosnev, Charlotte Junkuhn, Anna Luzie Walter, Dominik Paul Modest

Cells· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
Dominik Paul Modest, Volker Heinemann, Philipp Schütt, Stefan Angermeier, Mike Haberkorn

J Cancer Res Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
John H Strickler, Takayuki Yoshino, Kendall Stevinson, Christian Stefan Eichinger, Christina Giannopoulou, Dominik Paul Modest

Oncologist· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
Sebastian Stintzing, Kathrin Heinrich, David Tougeron, Dominik Paul Modest, Ingo Schwaner

J Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Alexej Ballhausen, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Dominik Paul Modest

Eur J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body composition is associated with disease aetiology and prognosis in patients undergoing resection of intrahepatic cholangiocarcinoma.
Isabella Lurje, Deniz Uluk, Sandra Pavicevic, Minh Duc Phan, Dennis Eurich, Dominik Paul Modest

Cancer Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
Arndt Stahler, Beeke Hoppe, Il-Kang Na, Luisa Keilholz, Lothar Müller, Dominik Paul Modest

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Vascular Endothelial Growth Factor Protects against the Development of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Wild-Type but Not in CD39-Null Mice.
Sebastian Knitter, Gregor Duwe, Anika Sophie Beierle, Sina Pesthy, Paul Viktor Ritschl, Dominik Paul Modest

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation.
Ramin Raul Ossami Saidy, Elisa Wegener, Deniz Uluk, Luca Dittrich, Wenzel Schöning, Dominik Paul Modest

Medicina (Kaunas)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis